Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AADI Aadi Bioscience	$1.60 -1.2%	$1.89	$1.21 ▼ $3.81	$39.52M	0.68	261,100 shs	140,334 shs
AGE AgeX Therapeutics		$4.54	$11.07 ▼ $35.71	$11.99M	1.18	3,849 shs	3,700 shs
EGRX Eagle Pharmaceuticals	$3.20	$3.11	$1.50 ▼ $3.87	$41.56M	0.83	7,182 shs	N/A
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	44 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AADI Aadi Bioscience	-1.23%	-8.57%	-17.95%	-6.98%	+15.11%
AGE AgeX Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
EGRX Eagle Pharmaceuticals	0.00%	+0.31%	-13.28%	+64.95%	-17.31%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AADI Aadi Bioscience	0.5113 of 5 stars	1.0	0.0	0.0	0.0	0.6	2.5	1.3
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AADI Aadi Bioscience	2.00	Hold	$1.67	4.17% Upside
AGE AgeX Therapeutics	0.00	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AADI Aadi Bioscience	$25.07M	1.58	N/A	N/A	$4.29 per share	0.37
AGE AgeX Therapeutics	$140K	0.00	N/A	N/A	($16.07) per share	0.00
EGRX Eagle Pharmaceuticals	$257.55M	0.16	$8.00 per share	0.40	N/A	∞
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AADI Aadi Bioscience	-$65.76M	-$2.35	N/A	N/A	N/A	-246.06%	-71.87%	-57.28%	11/4/2025 (Estimated)
AGE AgeX Therapeutics	-$14.80M	-$13.03	N/A	N/A	N/A	-10,424.65%	N/A	-120.90%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AADI Aadi Bioscience	N/A	N/A	N/A	N/A	N/A
AGE AgeX Therapeutics	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AADI Aadi Bioscience	N/A	4.89	4.54
AGE AgeX Therapeutics	N/A	0.13	0.36
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.12	0.85	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AADI Aadi Bioscience	52.08%
AGE AgeX Therapeutics	12.50%
EGRX Eagle Pharmaceuticals	85.36%
NBRV Nabriva Therapeutics	0.27%

Insider Ownership

Company	Insider Ownership
AADI Aadi Bioscience	37.30%
AGE AgeX Therapeutics	6.50%
EGRX Eagle Pharmaceuticals	28.90%
NBRV Nabriva Therapeutics	1.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AADI Aadi Bioscience	40	24.70 million	15.49 million	Optionable
AGE AgeX Therapeutics	5	1.08 million	1.01 million	Not Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable

AGE, NBRV, AADI, and EGRX Headlines

Recent News About These Companies

Nabriva Therapeutics plc (NBRVF)

October 19, 2024 | finance.yahoo.com

Meitheal gains rights to Contempo

July 20, 2024 | thepharmaletter.comT

Meitheal gains rights to CONTEPO from Nabriva in North America

July 19, 2024 | pharmaceutical-technology.comP

Nabriva Therapeutics PLC NBRVF

April 13, 2024 | morningstar.comM

Nabriva Therapeutics files patent for a dosing regimen for fosfomycin treatment

December 22, 2023 | pharmaceutical-technology.comP

Arbutus Biopharma Corporation: Arbutus Appoints Two New Executives

July 11, 2023 | finanznachrichten.de

NBRV - Nabriva Therapeutics plc

May 26, 2023 | finance.yahoo.com

Bacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029

February 28, 2023 | marketwatch.com

NBRV Nabriva Therapeutics plc

February 25, 2023 | seekingalpha.com

Nabriva Therapeutics Provides Corporate Update

January 6, 2023 | finance.yahoo.com

Nabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial Data

November 28, 2022 | marketwatch.com

Nabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic Fibrosis

November 28, 2022 | markets.businessinsider.com

Nabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock Up

November 28, 2022 | markets.businessinsider.com

Nabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | bizjournals.com

Nabriva gains after announcing Phase 1 data for cystic fibrosis candidate

November 28, 2022 | seekingalpha.com

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

November 28, 2022 | finance.yahoo.com

Nabriva's stock is up after sharing antibiotic news

November 28, 2022 | finance.yahoo.com

Nabriva's antibiotic shows promise as a potential cystic fibrosis treatment

November 28, 2022 | finance.yahoo.com

Nabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infections

November 10, 2022 | bioworld.comB

Montgomery County biopharmaceutical firm reducing workforce by 40%

November 10, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Top Headlines

View All

AGE, NBRV, AADI, and EGRX Company Descriptions

Aadi Bioscience NASDAQ:AADI

$1.60 -0.02 (-1.23%)

As of 08/15/2025

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.

AgeX Therapeutics NYSE:AGE

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.20 0.00 (0.00%)

As of 08/15/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time